Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications

References

• Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63(2):437–459. doi:10.1124/pr.110.00353321436344
   PubMed Web of Science ®Google Scholar
• Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011;123(15):1661–1670. doi:10.1161/CIRCULATIONAHA.109.91482021502584
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present, and future. Trends Phamacol Sci. 2004;25(4):193–200. doi;10.1016/j.tips.2004.02.007
   Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Table of Pharmacogenomic Biomarkers in Drug Labeling. Maryland: Food and Drug Administration: 2019.
   Google Scholar
• Van Booven D, Marsh S, McLeod H, et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010;20;4:277–281.20150829
   PubMed Web of Science ®Google Scholar
• Shirasaka Y, Chaudhry AS, Mcdonald M, et al. Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J. 2015;16(4):375–387. doi:10.1038/tpj.2015.5826323597
   PubMed Web of Science ®Google Scholar
• Abbasi K. The World Bank and World Health Focus on South Asia—I: Bangladesh. Bmj. 1999;318(7190):1066–1069. doi;10.1136/bmj.318.7190.106610205111
   PubMed Web of Science ®Google Scholar
• Huang TS, Zhang L, He Q, et al. DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation. Australas Phys Eng Sci Med. 2017;40(1):249–258. doi:10.1007/s13246-016-0519-x28083852
   PubMed Web of Science ®Google Scholar
• Krasniqi V, Dimovski A, Bytyqi HQ, Eftimov A, Šimičević L, Božina N. Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population. Arh Hig Rada Toksikol. 2017;68(3):180–184. doi:10.1515/aiht-2017-68-299828976882
   PubMed Web of Science ®Google Scholar
• Ancker S, Rechel B. Policy responses to HIV/AIDS in Central Asia. Glob Public Health. 2015;10(7):817–833. doi;10.1080/17441692.2015.104331326189875
   PubMed Web of Science ®Google Scholar
• Dodgen TM, Hochfeld WE, Fickl H, et al. Introduction of the AmpliChip CYP450 test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet. 2013;14:1. doi:10.1186/1471-2350-14-2023295100
   PubMed Web of Science ®Google Scholar
• Lee JH, Ahn SG, Lee J-W, et al. Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction. Platelets. 2015;27(4):301–307. doi:10.3109/09537104.2015.109587526556524
   PubMed Web of Science ®Google Scholar
• Hamdy SI, Hiratsuka M, Narahara K, et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol. 2002;53(6):596–603. doi:10.1046/j.1365-2125.2002.01604.x12047484
   PubMed Web of Science ®Google Scholar
• Li J, Wang Y, Wang H. Distribution of CYP2C19 polymorphisms in Mongolian and Han nationals and the choice of specific antiplatelet drugs. Int J Clin Pharm. 2017;39(4):791–797. doi:10.1007/s11096-017-0451-528597175
   PubMed Web of Science ®Google Scholar
• Rajman I, Knapp L, Morgan T, Masimirembwa C. African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development. EBioMedicine. 2017;17:67–74. doi:10.1016/j.ebiom.2017.02.01728237373
   PubMed Web of Science ®Google Scholar
• Hodel EMS, Csajka C, Ariey F, et al. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother. 2012;57(2):950–958. doi:10.1128/AAC.01700-1223229480
   PubMed Web of Science ®Google Scholar
• Ismail R, Hussein A, Teh LK, Isa MN. CYP2D6 phenotypes among Malays in Malaysia. J Clin Pharm Ther. 2008;25(5):379–383. doi:10.1111/j.1365-2710.2000.00304.x
   Google Scholar
• Ellison CA, El-Ella SSA, Tawfik M, Lein PJ, Olson JR. Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers. J Toxicol Environ Health A. 2012;75(4):232–241. doi:10.1080/15287394.2012.64120122352331
   PubMed Web of Science ®Google Scholar
• Yen-Revollo JL, Booven DJV, Peters EJ, et al. Influence of ethnicity on pharmacogenetic variation in the Ghanaian population. Pharmacogenomics J. 2009;9(6):373–379. doi:10.1038/tpj.2009.2819546880
   PubMed Web of Science ®Google Scholar
• Barlas IÖ, Sezgin O, Dandara C, et al. Harnessing knowledge on very important pharmacogenes CYP2C9 and CYP2C19 variation for precision medicine in resource-limited global conflict zones. Omics. 2016;20(10):604–609. doi:10.1089/omi.2016.013327726640
   PubMed Web of Science ®Google Scholar
• Bagheri A, Kamalidehghan B, Haghshenas M, et al. Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities. Drug Des Devel Ther. 2015;9:2627–2634.
   Web of Science ®Google Scholar
• Müller-Nordhorn J, Holmberg C, Dokova KG, et al. Perceived challenges to public health in Central and Eastern Europe: a qualitative analysis. BMC Public Health. 2012;12:1. doi:10.1186/1471-2458-12-31122214479
   PubMed Web of Science ®Google Scholar
• Kozak M, Bornmann L, Leydesdorff L. How have the Eastern European countries of the former Warsaw Pact developed since 1990? A bibliometric study. Scientometrics. 2014;102:1101–1117. doi:10.1007/s11192-014-1439-825632165
   PubMed Web of Science ®Google Scholar
• Kawalec P, Tesar T, Vostalova L, et al. Pharmaceutical regulation in Central and Eastern European Countries: a current review. Front Pharmacol 2017;8:892. doi:10.3389/fphar.2017.00892
   Google Scholar
• Vollset SE. Does the southern European cardiovascular mortality advantage extend to total mortality? 50-year trends in death risks between 40 and 70 years of age in Western European men and women. Scand J Public Health. 2010;38(5 Suppl):127–134. doi:10.1177/140349481037989321062847
   PubMed Web of Science ®Google Scholar
• Koopmans AB, Vinkers DJ, Gelan PJ, Hoek HW, Harten PNV. CYP2D6 and CYP2C19 genotyping in psychiatric patients on psychotropic medication in the former Dutch Antilles. Pharmacogenomics. 2017;18(10):1003–1012. doi:10.2217/pgs-2017-001128639468
   PubMed Web of Science ®Google Scholar
• Shrif NEMA, Won -H-H, Lee S-T, et al. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. Eur J Clin Pharmacol. 2011;67(11):1119–1130. doi:10.1007/s00228-011-1060-121590310
   PubMed Web of Science ®Google Scholar
• United Nations Statistics Division. Standard Country or Area Codes for Statistical Use (M49). New York: United Nations Statistics Division; 2011.
   Google Scholar
• Soko ND, Masimirembwa C, Dandara C. Pharmacogenomics of Rosuvastatin: a Glocal (Global Local) African perspective and expert review on a statin drug. Omics. 2016;20(9):498–509. doi:10.1089/omi.2016.011427631189
   PubMed Web of Science ®Google Scholar
• Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics. 2002;12(5):375–383.12142727
   PubMedGoogle Scholar
• Herrlin K, Massele AY, Jande M, et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype*. Clin Pharmacol Ther. 1998;64(4):391–401. doi:10.1016/S0009-9236(98)90070-49797796
   PubMed Web of Science ®Google Scholar
• Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet. 2009;10:1. doi:10.1186/1471-2350-10-12419133158
   PubMed Web of Science ®Google Scholar
• Cavaco I, Stromberg-Norklit J, Kaneko A, et al. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol. 2005;61(1):15–18. doi:10.1007/s00228-004-0871-815785959
   PubMed Web of Science ®Google Scholar
• Allabi AC, Gala J-L, Desager J-P, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the and Belgian populations. Br J Clin Pharmacol. 2003;56(6):653–657. doi:10.1046/j.1365-2125.2003.01937.x14616425
   PubMed Web of Science ®Google Scholar
• Miura J, Obua C, Abbo C, Kaneko S, Tateishi T. Cytochrome P450 2C19 genetic polymorphisms in Ugandans. Eur J Clin Pharmacol. 2008;65(3):319–320. doi:10.1007/s00228-008-0583-619002442
   PubMed Web of Science ®Google Scholar
• Wright GEB, Niehaus DJH, Drögemöller BI, Koen L, Gaedigk A, Warnich L. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet. 2010;74(4):340–350. doi:10.1111/j.1469-1809.2010.00585.x20597905
   PubMed Web of Science ®Google Scholar
• Jittikoon J, Mahasirimongkol S, Charoenyingwattana A, et al. Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. J Hum Genet. 2015;61(2):119–127. doi:10.1038/jhg.2015.11526423926
   PubMed Web of Science ®Google Scholar
• Pedersen RS, Brasch-Andersen C, Sim SC, et al. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol. 2010;66(12):1199–1205. doi:10.1007/s00228-010-0864-820665013
   PubMed Web of Science ®Google Scholar
• Hilli J, Rane A, Lundgren S, Bertilsson L, Laine K. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. Fundam Clin Pharmacol. 2007;21(4):379–386. doi:10.1111/j.1472-8206.2007.00494.x17635176
   PubMed Web of Science ®Google Scholar
• Dandara C, Lombard Z, Plooy ID, Mclellan T, Norris SA, Ramsay M. Genetic variants in CYP (−1A2, −2C9, −2C19, −3A4 and −3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics. 2011;12(12):1663–1670. doi:10.2217/pgs.11.10622118051
   PubMed Web of Science ®Google Scholar
• Yampayon K, Sukasem C, Limwongse C, et al. Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. Eur J Clin Pharmacol. 2017;73(7):855–865. doi:10.1007/s00228-017-2250-228391407
   PubMed Web of Science ®Google Scholar
• Ramsjö M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh H-K, Bertilsson L. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol. 2010;66(9):871–877. doi:10.1007/s00228-010-0835-020499227
   PubMed Web of Science ®Google Scholar
• Scordo M. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res. 2004;50(2):195–200. doi:10.1016/j.phrs.2004.01.00415177309
   PubMed Web of Science ®Google Scholar
• Ruas JL, Lechner MC. Allele frequency of CYP2C19 in a Portuguese population. Pharmacogenetics. 1997;7(4):333–335.9295062
   PubMedGoogle Scholar
• Payan M, Rouini MR, Tajik N, Ghahremani MH, Tahvilian R. Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population. Daru. 2014;22:1. doi:10.1186/2008-2231-22-3124386961
   PubMed Web of Science ®Google Scholar
• Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe*. Clin Pharmacol Ther. 1995;57(6):656–661. doi:10.1016/0009-9236(95)90228-77781265
   PubMed Web of Science ®Google Scholar
• Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Hørder M, Brøsen K. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol. 2001;48(3):395–401. doi:10.1046/j.1365-2125.1999.00019.x
   Web of Science ®Google Scholar
• Ji L, Pan S, Marti-Jaun J, Hanseler E, Rentsch K, Hersberger M. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14b allele in mainland Chinese. Clin Chem. 2002;48(7):983–988.12089164
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Coetsee C. The CYP2D6 gene locus in South African coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol. 2008;64(5):465–475. doi:10.1007/s00228-007-0445-718202841
   PubMed Web of Science ®Google Scholar
• Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996;278(1):441–446.8764380
   PubMed Web of Science ®Google Scholar
• Sankar PA, Cho MK, Mountain J. Race and ethnicity in genetic research. Am J Med Genet A. 2007;143(9):961–970. doi:10.1002/ajmg.a.31575
   Web of Science ®Google Scholar
• Bluth MH, Li J. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmgenomics Pers Med. 2011;4:11–33. doi:10.2147/PGPM.S1886123226051
   PubMedGoogle Scholar
• Johnson JA. Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics. 2013;14(7):835–843. doi:10.2217/pgs.13.5223651030
   PubMed Web of Science ®Google Scholar
• McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag. 2007;3(5):753–759.
   Google Scholar
• Finkelstein J, Friedman C, Hripcsak G, Cabrera M. Potential utility of precision medicine for older adults with polypharmacy: a case series study. Pharmgenomics Pers Med. 2016;9:31–45. doi:10.2147/PGPM.S10147427143951
   PubMed Web of Science ®Google Scholar
• Finkelstein J, Friedman C, Hripcsak G, Cabrera M. Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study. Pharmgenomics Pers Med. 2016;9:107–116. doi:10.2147/PGPM.S11701427789970
   PubMed Web of Science ®Google Scholar
• Liu J, Finkelstein J. Towards pharmacogenomics-driven medication risk assessment in people with polypharmacy. Stud Health Technol Inform. 2018;247:880–884.29678087
   PubMedGoogle Scholar
• Ortega VE, Meyers DA. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol. 2014;133(1):16–26. doi:10.1016/j.jaci.2013.10.04024369795
   PubMed Web of Science ®Google Scholar
• Lakiotaki K, Kanterakis A, Kartsaki E, Katsila T, Patrinos GP, Potamias G. Exploring public genomics data for population pharmacogenomics. PLoS One. 2017;12(8):e0182138. doi:10.1371/journal.pone.018213828771511
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol. 2003;43(9):943–967.12971027
   PubMed Web of Science ®Google Scholar
• Ramamoorthy A, Pacanowski MA, Bull J, Zhang L. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther. 2015;97(3):263–273. doi:10.1002/cpt.6125669658
   PubMed Web of Science ®Google Scholar
• Wu AH, Wang P, Smith A, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics. 2008;9(2):169–178. doi:10.2217/14622416.9.2.16918370846
   PubMed Web of Science ®Google Scholar
• Limdi NA, Brown TM, Yan Q, et al. Race influences warfarin dose changes associated with genetic factors. Blood. 2015;126(4):539–545. doi:10.1182/blood-2015-02-62704226024874
   PubMed Web of Science ®Google Scholar
• Johnson JA. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation. 2008;118(13):1383–1393. doi:10.1161/CIRCULATIONAHA.107.70402318809808
   PubMed Web of Science ®Google Scholar
• Julius S, Alderman M, Beevers G. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy. The LIFE study. J Am Coll Cardiol. 2004;43(6):1047–1055. doi:10.1016/j.jacc.2003.11.02915028365
   PubMed Web of Science ®Google Scholar
• Urban TJ. Race, ethnicity, ancestry, and pharmacogenetics. Mt Sinai J Med. 2010;77(2):133–139. doi:10.1002/msj.2016820309922
   PubMed Web of Science ®Google Scholar
• Cohn J, Archibald D, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study. N Engl J Med. 1986;314(24):1547–1552. doi:10.1056/NEJM1986061231424043520315
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in Blacks with heart failure. N Engl J Med. 2004;35(20):2049–2057. doi:10.1056/NEJMoa042934
   Web of Science ®Google Scholar
• Bernard S. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006;11(2):126–135. doi:10.1634/theoncologist.11-2-12616476833
   PubMed Web of Science ®Google Scholar
• Fricke-Galindo I, Cespedes-Garro C, Rodrigues-Soares F, et al. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J. 2016;16(2):113–123. doi:10.1038/tpj.2015.7026503820
   PubMed Web of Science ®Google Scholar
• Sychev D, Shuev G, Suleymanov S, et al. Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations. Pharmgenomics Pers Med. 2017;10:93–99. doi:10.2147/PGPM.S12966528435307
   PubMed Web of Science ®Google Scholar
• Yang Z, Cui H, Hasi T, Jia S, Gong M, Su X. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. Genet Mol Res. 2010;9(3):1844–1851. doi:10.4238/vol9-3gmr93820845310
   PubMed Web of Science ®Google Scholar
• Goh LL, Lim CW, Sim WC, Toh LX, Leong KP. Analysis of genetic variation in CYP450 genes for clinical implementation. PLoS One. 2017;12:1. doi:10.1371/journal.pone.0169233
   Web of Science ®Google Scholar
• Jalil NJA, Bannur Z, Derahman A, et al. The implication of the polymorphisms of COX-1, UGT1A6, and CYP2C9 among cardiovascular disease (CVD) patients treated with aspirin. J Pharm Pharm Sci. 2015;18(3):474–483.26517138
   PubMed Web of Science ®Google Scholar
• Mizzi C, Dalabira E, Dzimiri N, et al. A European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS One. 2016;11(9):e0162866. doi: 10.1371/journal.pone.0162866
   Web of Science ®Google Scholar
• Bhopal R. Is research into ethnicity and health racist, unsound, or important science? Bmj. 1997;314(7096):1751–1756. doi:10.1136/bmj.314.7096.17519202509
   PubMed Web of Science ®Google Scholar
• Smedley A, Smedley BD. Race as biology is fiction, racism as a social problem is real: anthropological and historical perspectives on the social construction of race. Am Psychol. 2005;60(1):16–26. doi:10.1037/0003-066X.60.1.1615641918
   PubMed Web of Science ®Google Scholar
• Guo G, Fu Y, Lee H, Cai T, Harris KM, Li Y. Genetic bio-ancestry and social construction of racial classification in social surveys in the contemporary United States. Demography. 2013;51(1):141–172. doi:10.1007/s13524-013-0242-0
   Web of Science ®Google Scholar
• Parra EJ, Kittles RA, Argyropoulos G, et al. Ancestral proportions and admixture dynamics in geographically defined African Americans living in South Carolina. Am J Phys Anthropol. 2001;114(1):18–29. doi:10.1002/1096-8644(200101)114:1<18::AID-AJPA1002>3.0.CO;2-211150049
   PubMed Web of Science ®Google Scholar
• Lind JM, Hutcheson-Dilks HB, Williams SM, et al. Elevated male European and female African contributions to the genomes of African American individuals. Hum Genet. 2006;120(5):713–722. doi:10.1007/s00439-006-0261-717006671
   PubMed Web of Science ®Google Scholar
• Tishkoff S, Reed F, Friedlander F, Ehret C, Ranciaro A, Froment A. The genetic structure and history of Africans and African Americans. Science. 2009;324(5930):1035–1044. doi:10.1126/science.117225719407144
   PubMed Web of Science ®Google Scholar
• Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Community Health. 2004;58(6):441–445. doi:10.1136/jech.2003.01346615143107
   PubMed Web of Science ®Google Scholar
• National Center for Complementary and Integrative Health. Racial and Ethnic Categories and Definitions for NIH Diversity Programs and for Other Reporting Purposes. Bethesda, Maryland: National Institutes of Health; 2015.
   Google Scholar
• Hunt LM, Megyesi MS. The ambiguous meanings of the racial/ethnic categories routinely used in human genetics research. Soc Sci Med. 2008;66(2):349–361. doi:10.1016/j.socscimed.2007.08.03417959289
   PubMed Web of Science ®Google Scholar
• Avilés-Santa ML, Heintzman J, Lindberg NM, et al. Personalized medicine and Hispanic health: improving health outcomes and reducing health disparities - a National Heart, Lung, and Blood Institute workshop report. BMC Proc. 2017;11(Suppl 11):11. doi:10.1186/s12919-017-0079-429149222
   PubMedGoogle Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417. doi:10.1038/clpt.2012.9622992668
   PubMed Web of Science ®Google Scholar
• Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89(3):464–467. doi:10.1038/clpt.2010.27921270786
   PubMed Web of Science ®Google Scholar
• Zuo J, Xia D, Jia L, Guo T. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie. 2012;67(7):639–644.22888523
   PubMed Web of Science ®Google Scholar
• Chan SL, Samaranayake N, Ross CJ, et al. Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenet Genomics. 2016;26(1):28–39. doi:10.1097/FPC.000000000000018226444257
   PubMed Web of Science ®Google Scholar
• Ang GY, Yu CY, Subramaniam V, et al. Detection of CYP2C19 genetic variants in malaysian orang asli from massively parallel sequencing data. PLoS One. 2016;11:10. doi:10.1371/journal.pone.0164169
   Web of Science ®Google Scholar
• Mirzaev KB, Sychev DA, Ryzhikova KA, et al. Genetic polymorphisms of cytochrome P450 enzymes and transport proteins in a russian population and three ethnic groups of dagestan. Genet Test Mol Biomarkers. 2017;21(12):747–753. doi:10.1089/gtmb.2017.003629023140
   PubMed Web of Science ®Google Scholar
• Nakai K, Habano W, Nakai K, et al. Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sci. 2005;78(1):107–111. doi:10.1016/j.lfs.2005.04.04916111713
   PubMed Web of Science ®Google Scholar
• Halling J, Petersen MS, Damkier P, et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol. 2005;61(7):491–497. doi:10.1007/s00228-005-0938-116025294
   PubMed Web of Science ®Google Scholar
• Scordo MG, Aklillu E, Yasar U, Dahl M-L, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol. 2001;52(4):447–450. doi:10.1046/j.0306-5251.2001.01460.x11678789
   PubMed Web of Science ®Google Scholar
• Matimba A, Oluka MN, Ebeshi BU, et al. Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet. 2008;16(7):780–783. doi:10.1038/ejhg.2008.4918382479
   PubMed Web of Science ®Google Scholar
• Dandara C, Masimirembwa CM, Magimba A, et al. Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients. Eur J Clin Pharmacol. 2001;57(1):11–17.11372584
   PubMed Web of Science ®Google Scholar
• Rodrigues-Soares F, Kehdy FSG, Sampaio-Coelho J, et al. Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative. Pharmacogenomics J. 2018. doi:10.1038/s41397-018-0015-7
   Web of Science ®Google Scholar
• Gaieski JB, Owings AC, Vilar MG, et al. Genetic ancestry and indigenous heritage in a Native American Descendant Community in Bermuda. Am J Phys Anthropol. 2011;146(3):392–405. doi:10.1002/ajpa.2158821994016
   PubMed Web of Science ®Google Scholar
• Rebbeck TR. Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol. 2017;27(1):3–10. doi:10.1016/j.semradonc.2016.08.00227986209
   PubMed Web of Science ®Google Scholar
• Zeigler-Johnson CM, Spangler E, Jalloh M, Gueye S, Rennert H, Rebbeck T. Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. Can J Urol. 2008;15(1):3872–3882.18304397
   PubMed Web of Science ®Google Scholar
• Ferrell PB, Mcleod HL. Carbamazepine,HLA-B*1502and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543–1546. doi:10.2217/14622416.9.10.154318855540
   PubMed Web of Science ®Google Scholar
• Chung W-H, Hung S-I, Hong H-S, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004;428(6982):486. doi:10.1038/nature0243715057820
   PubMed Web of Science ®Google Scholar
• Braun L, Fausto-Sterling A, Fullwiley D, et al. Racial categories in medical practice: how useful are they? PLoS Med. 2007;4:9. doi:10.1371/journal.pmed.0040271
   Web of Science ®Google Scholar
• Race, Ethnicity, and Genetics Working Group. The use of racial, ethnic, and ancestral categories in human genetics research. Am J Hum Genet. 2005;77(4):519–532. doi:10.1086/49174716175499
   PubMed Web of Science ®Google Scholar
• Coon CS. The Living Races of Man. New York: Alfred A. Knopf; 1974.
   Google Scholar
• Stoneking M. Human origins. The molecular perspective. EMBO Rep. 2008;9(Suppl 1):S46–S50. doi:10.1038/embor.2008.6418578025
   PubMed Web of Science ®Google Scholar
• Hunt LM, Megyesi MS. Genes, race and research ethics: whos minding the store? J Med Ethics. 2008;34(6):495–500. doi:10.1136/jme.2007.02129518511627
   PubMed Web of Science ®Google Scholar
• Mao X, Bigham AW, Mei R, et al. A genomewide admixture mapping panel for Hispanic/Latino populations. Am J Hum Genet. 2007;80(6):1171–1178. doi:10.1086/51856417503334
   PubMed Web of Science ®Google Scholar
• Price AL, Patterson N, Yu F, et al. A genomewide admixture map for Latino populations. Am J Hum Genet. 2007;80(6):1024–1036. doi:10.1086/51831317503322
   PubMed Web of Science ®Google Scholar
• Montinaro F, Busby GB, Pascali VL, Myers S, Hellenthal G, Capelli C. Unravelling the hidden ancestry of American admixed populations. Nat Commun. 2015;6(1):6596. doi:10.1038/ncomms759625803618
   PubMed Web of Science ®Google Scholar
• Torgerson DG, Gignoux CR, Galanter JM, et al. Case-control admixture mapping in Latino populations enriches for known asthma-associated genes. J Allergy Clin Immunol. 2012;130(1):76–82. doi:10.1016/j.jaci.2012.02.04022502797
   PubMed Web of Science ®Google Scholar
• Daviglus ML, Talavera GA, Avilés-Santa ML, et al. Prevalence of Major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States. Jama. 2012;308(17):1775–1784. doi:10.1001/jama.2012.1451723117778
   PubMed Web of Science ®Google Scholar
• Conomos M, Laurie C, Stilp A, et al. Genetic diversity and association studies in US Hispanic/Latino populations: applications in the Hispanic Community Health Study/Study of Latinos. Am J Hum Genet. 2016;98(1):165–184. doi:10.1016/j.ajhg.2015.12.00126748518
   PubMed Web of Science ®Google Scholar
• 1000 Genomes Project Consortium; Auton A, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74.
   Web of Science ®Google Scholar
• Tian C, Kosoy R, Lee A, et al. Analysis of East Asia genetic substructure using genome-wide SNP arrays. PLoS One. 2008;3:12. doi:10.1371/journal.pone.0003862
   Web of Science ®Google Scholar
• Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet. 2008;9(1):403–433. doi:10.1146/annurev.genom.9.081307.16425818593304
   PubMed Web of Science ®Google Scholar
• Solovieff N, Hartley SW, Baldwin CT, Perls TT, Steinberg MH, Sebastiani P. Clustering by genetic ancestry using genome-wide SNP data. BMC Genet. 2010;11(1):108. doi:10.1186/1471-2156-11-10821143920
   PubMed Web of Science ®Google Scholar
• Fujimura JH, Rajagopalan R. Different differences: the use of ‘genetic ancestry’ versus race in biomedical human genetic research. Soc Stud Sci. 2010;41(1):5–30. doi:10.1177/0306312710379170
   Web of Science ®Google Scholar
• Nebert DW, Menon AG. Pharmacogenomics, ethnicity, and susceptibility genes. Pharmacogenomics J. 2001;1(1):19–22.11913722
   PubMedGoogle Scholar
• Risch N, Burchard E, Ziv E, Tang H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol. 2002;3(7):comment2007. doi:10.1186/gb-2002-3-7-comment200712184798
   PubMedGoogle Scholar
• Wilson JF, Weale ME, Smith AC, et al. Population genetic structure of variable drug response. Nat Genet. 2001;29(3):265–269. doi:10.1038/ng76111685208
   PubMed Web of Science ®Google Scholar
• Lee SS. Racializing drug design: implications of pharmacogenomics for health disparities. Am J Public Health. 2005;95(12):2133–2138. doi:10.2105/AJPH.2005.06867616257939
   PubMed Web of Science ®Google Scholar
• Bonham VL, Callier SL, Royal CD. Will precision medicine move us beyond race? N Engl J Med. 2016;374(21):2003–2005. doi:10.1056/NEJMp151129427223144
   PubMed Web of Science ®Google Scholar
• Cooper RS, Nadkarni GN, Ogedegbe G. Race, ancestry, and reporting in medical journals. Jama. 2018;320(15):1531–1532. doi:10.1001/jama.2018.1096030264132
   PubMed Web of Science ®Google Scholar
• Tang H, Quertermous T, Rodriguez B, et al. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet. 2005;76(2):268–275. doi:10.1086/42788815625622
   PubMed Web of Science ®Google Scholar
• Mersha TB, Abebe T. Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Hum Genomics. 2015;9:1. doi:10.1186/s40246-014-0023-x25563503
   PubMed Web of Science ®Google Scholar
• Bonham VL, Sellers SL, Gallagher TH, et al. Physicians attitudes toward race, genetics, and clinical medicine. Genet Med. 2009;11(4):279–286. doi:10.1097/GIM.0b013e318195aaf419265721
   PubMed Web of Science ®Google Scholar
• Tamminga W, Wemer J, Oosterhuis B, Zeeuw RD, Leij LD, Jonkman J. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol. 2001;57(10):717–722.11829201
   PubMed Web of Science ®Google Scholar
• Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics. 1996;6(6):521–526.9014201
   PubMedGoogle Scholar
• Matimba A, Del-Favero J, Broeckhoven CV, Masimirembwa C. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics. 2009;3(2):169. doi:10.1186/1479-7364-3-2-16919164093
   PubMedGoogle Scholar